

Reference: FOI.ICB-2425/145

Subject: Wegovy Prescribing & Weight Management Services

I can confirm that the ICB does hold some of information requested; please see responses below:

QUESTION	RESPONSE
1. Does your ICB currently fund prescription of semaglutide 2.4mg (Wegovy) within specialist weight management services?	The ICB commissions a Tier 3 weight management service which includes pharmacotherapy such as Wegovy. However, the services are currently closed to new referrals whilst waiting list backlogs are being addressed.
2. Please name the specialist weight management services you commission	North Bristol NHS Trust (NBT) and Oviva.
3. If you do not commission a specialist weight management service, please name any specialist weight management services that operate within your ICB geography that you are aware of and are not commissioned?	N/A
4. Are there any additional criteria used to restrict eligibility in your ICB for semaglutide 2.4 mg (Wegovy) outside of the recommendations in NICE TA875?	Semaglutide (Wegovy) is licensed for use in certain patients with a BMI >35 and Non-diabetic hyperglycaemia, and NICE have given recommendations on its use under NICE TA875 and we would expect this medication to be prescribed in line with this guidance. A locally agreed pathway to access this treatment is being put in place that allows prescribing in secondary care weight management

	clinic, but only if the current criteria for a weight management referral are met - https://bnssg.icb.nhs.uk/directory/weight-management-service-tier-3-and-tier-4-service/. Suitable patients will be supported and prescribed treatment for up to 2 years. Patients who do not meet the criteria will not be able to access this treatment on the NHS at this time See: https://remedy.bnssg.icb.nhs.uk/adults/weight-management/tier-3-4-weight-management-service-bnssg/
5. Since 8th March 2023, how many letters of complaint has your ICB received from patients who feel they should receive semaglutide 2.4 mg (Wegovy)?	The ICB has received less than 5 complaints regarding semaglutide/Wegovy during the requested date range.
6. If you do not currently fund semaglutide 2.4 mg (Wegovy), is the ICB working to implement this?	N/A
7. If you are looking to implement semaglutide 2.4 mg (Wegovy), is it projected to be funded by your ICB before April 2025?	N/A

The information provided in this response is accurate as of 23 July 2024 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.